相关实验视频
Updated: May 16, 2025
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
930
阿布罗西提尼布治疗方式:对亚托皮肤炎预后和复发率的影响
Sisi Deng1, Jiong Fu2, Xueqin Chen1
1From the Department of Dermatology, Southwest Hospital, Army Medical University, Chongqing, China.
Dermatitis : contact, atopic, occupational, drug
|April 2, 2025
概括
持续治疗abrocitinib和完成12周的诱导改善了中度至严重的亚托皮炎 (AD) 患者的结果,降低了复发率.
科学领域:
- 皮肤病学 皮肤病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 阿布罗西替尼在中度至重度的亚托皮性皮肤炎 (AD) 中有效.
- 关于abrocitinib治疗模式和预后的现实世界证据有限.
- 关于不同阿布罗西提尼布疗法对阿尔茨海默病预后的影响的研究缺乏.
研究的目的:
- 为了研究不同abrocitinib治疗方案对AD预后的影响.
- 为了比较持续,逐渐和停止使用abrocitinib的结果.
- 根据治疗持续时间和强度评估复发率.
主要方法:
- 对接受abrocitinib的中度至重度AD患者进行了回顾性研究.
- 在西南医院从2023年8月到2024年4月收集的数据.
- 患者被分为维持,逐渐减少或停止治疗组. 疾病后控制.
主要成果:
- 维持组 (100 mg/天) 在33.3%的患者中实现了EASI-75和58.3%的患者中实现了pp-NRS4.
- 在完成12周诱导期的患者中,SCORAD,EASI,PNS和DLQI的显著改善被观察到.
- 与停止治疗相比,持续治疗和启动完成与更长的复发时间有关.
结论:
- 持续的阿布罗西替尼治疗与阿尔茨海默病的改善结果有关.
- 完成12周的诱导期可以改善预后并降低复发率.
- 治疗方式对接受abrocitinib的中度至重度AD患者的长期预后产生重大影响.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
109
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
109
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
91
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
91
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
103
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
103
01:29Inflammatory Bowel Disease IV: Pharmacological Management
82
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
82
01:20The JAK-STAT Signaling Pathway
8.5K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.5K